TABLE 1

TV and Percentage Change in TV on Day 45 of Study

Treatment	n	TV (mm³) on day 0 of study (mean ± SD)	TV (mm³) on day 45 of study (mean ± SD)	Change in TV (%) on day 45 (mean ± SD)	Response rate (%)
PBS control	4	121.35 ± 43.09	1,069.52 ± 249.56	1,000.70 ± 537.93	0
⁹⁰Y-hu3S193 (0.46 MBq)	5	135.40 ± 27.86	750.04 ± 236.12	443.69 ± 79.52	0
⁹⁰Y-hu3S193 (0.92 MBq)	5	136.60 ± 25.35	513.51 ± 226.64 (P = 0.01)^*	293.14 ± 212.24 (P = 0.0295)^†	0
⁹⁰Y-hu3S193 (1.85 MBq)	3	142.00 ± 27.26	06.00 ± 10.39 (P = 0.0008)^*	−96.18 ± 6.62 (P = 0.0065)^†	33 PR/66 CR
⁹⁰Y-hu3S193 (3.70 MBq)	5	157.60 ± 37.08	00.00 ± 00.00 (P < 0.0001)^*	−100.00 ± 00.00 (P = 0.0023)^†	100 CR
⁹⁰Y-huA33 (0.46 MBq)	4	147.00 ± 36.01	1,139.93 ± 127.10	712.53 ± 233.94	0
⁹⁰Y-huA33 (0.92 MBq)	3	120.50 ± 54.84	959.56 ± 157.81	695.67 ± 595.06	0
⁹⁰Y-huA33 (1.85 MBq)	4	158.00 ± 44.68	791.72 ± 300.34	390.34 ± 55.19	0
⁹⁰Y-huA33 (3.70 MBq)	2	137.00 ± 25.43	612.14 ± 32.25	336.47 ± 101.21	0
TXL (600 μg)	5	152.00 ± 33.79	852.75 ± 353.44	458.15 ± 178.42	0
⁹⁰Y-hu3S193 (0.46 MBq + TXL)	5	127.60 ± 32.79	144.55 ± 107.91 (P = 0.0001)^*	16.99 ± 82.25 (P = 0.0046)^†	20 PR
⁹⁰Y-hu3S193 (0.92 MBq + TXL)	5	148.20 ± 24.08	110.95 ± 94.24 (P < 0.0001)^*	−28.79 ± 51.04 (P = 0.0034)^†	40 PR
⁹⁰Y-hu3S193 (1.85 MBq + TXL)	5	161.00 ± 35.08	00.00 ± 00.00 (P < 0.0001)^*	−100.00 ± 00.00 (P = 0.0023)^†	100 CR
⁹⁰Y-huA33 (0.46 MBq + TXL)	4	135.75 ± 39.68	660.46 ± 270.02	379.47 ± 85.09	0
⁹⁰Y-huA33 (0.92 MBq + TXL)	3	140.50 ± 25.68	237.79 ± 86.22 (P = 0.0029)^*	58.98 ± 56.92 (P = 0.0320)^†	0
⁹⁰Y-huA33 (1.85 MBq + TXL)	4	123.25 ± 24.10	198.92 ± 28.78 (P = 0.0004)^*	63.87 ± 22.74 (P = 0.0131)^†	0

↵* Results of significant t test comparing mean TV of placebo PBS control group with all other treatments.
↵† Results of significant t test comparing mean % change in TV from day 0 of placebo PBS control group with all other treatments.
n = number of mice; TXL = paclitaxel.